Global Xerostomia Therapeutics Market

Xerostomia Therapeutics Market Insights

Xerostomia is characterized as dry mouth caused by decreased or absent saliva flow. Xerostomia is a symptom of toxicity caused by chemotherapy, head, neck radiotherapy, drug side effects, autoimmune illness, or other diseases such as untreated asthma, viruses, and hormonal shifts. Xerostomia is normal in people who have Sjögren's syndrome or are undergoing radiation treatment for head and neck cancer. Xerostomia is a typical condition among the elderly, affecting approximately 20% of the global population. Additionally, xerostomia causes reduced salivary flow can make it significantly difficult to taste, chew, swallow, and speak; it can also increase the risk of developing dental decay, tooth demineralization, tooth irritation, and oral infections.

The expanded use of radiation therapy and chemotherapy is anticipated to accelerate the prevalence of xerostomia, which is presumed to stimulate the xerostomia therapeutics market. Key drivers influencing market growth encompass increasing prescription drug use, convenient accessibility & cost-effectiveness of drugs, a rising senile demographic pool, and an uptick in the incidence of disorders such as Sjogren's syndrome, HIV, diabetes, and Alzheimer's disease, among others. Furthermore, considerations including the lack of knowledge & the absence of appropriate treatment options are likely to impede the use of xerostomia therapeutics drugs and can serve as a limiting force for the xerostomia therapeutics market.

The major market drivers in the market of xerostomia therapeutics are the increasing incidence of related diseases, the most prevalent of which is Sjogren's syndrome, which is driving the rise of xerostomia. Sjogren's disease affects about 3.1 million people out of a total population of 4 million, according to the American College of Rheumatology. However, the xerostomia care demand may be slowed by factors such as a lack of understanding among people in emerging and underdeveloped countries. Another factor impeding the development of the xerostomia care market is the scarcity of successful treatments.

The intensified use of chemotherapy and radiotherapy in cancer care may harm the salivary glands. As a result, this has been a major cause for people seeking xerostomia treatments. The increase in diabetes cases globally has an effect on the salivary glands. Furthermore, taking medications can cause a variety of adverse effects, one of which is dry mouth. As a result, individuals are becoming more reliant on drugs, which is leading to the development of the xerostomia therapeutics market. Increasing self-reliance and understanding of the current situation is also fostering business development.

Some of the main forces driving demand growth are an expansion in attractive payout policies for xerostomia drugs, and also an uptick in responsiveness and knowledge regarding conditions correlated with the disease. The rising prevalence of xerostomia, as well as related clinical ailments such as Parkinson's disease, high blood pressure, Sjogren's syndrome, and diabetes, benefits the global market of xerostomia therapeutics. As per the Colgate-Palmolive Company, it is forecasted that more than 25 million individuals in the United States suffer from dry mouth. Likewise, the Sjogren Syndrome Foundation reports that more than four million individuals have Sjogren's syndrome, which is one of the disorders that trigger dry mouth. Conversely, in order to address this issue, this foundation conducts outreach campaigns in the United States for individuals who are recovering from this disease, as well as to empower the common population. This consideration has also contributed to the overall demand in this region's growth. Along with various foundations raising public consciousness, several large pharmaceutical firms are pursuing acquisitions & joint ventures with new corporations in order to expand their product offerings and raise public consciousness, thereby further propelling the global demand.

Xerostomia Therapeutics Market: By Product

Based on the products, the market of xerostomia therapeutics is divided into salivary stimulants, salivary substitutes, dentifrices in this market. The dentifrices category led the overall market in terms of sales due to its efficiency, availability, cost-effectiveness, and higher penetration among primary consumers. Salivary stimulants are predicted to rise the fastest throughout the forecast period. Salivary stimulants are available in a multitude of varieties, including mints, sugar-free chewing gums, sprays, and lozenges. Patients have easy accessibility to a broad variety of alternatives for each product. Both of the above considerations are foreseen to contribute to the segment's development.

Xerostomia Therapeutics Market: By Type

Based on the type, the xerostomia therapeutics market is categorized as OTC and Prescription. In terms of volume, the OTC segment contributed to the largest share and is foreseen to rise at a profitable CAGR throughout the forecast period. The supremacy is due to its vast range & affordability, protection & effectiveness, restricted availability of generic medications, and low product prices. Moreover, one of the market's primary driving factors is the easy availability of low-cost prescription OTC products, namely, mouthwashes, saliva replacement gels, sugar-free chewing gums, lozenges, toothpaste, and oral-adhering discs, pads, and melts.

Xerostomia Therapeutics Market: By Region

As per the geographical analysis, the market can be classified into North America (the US, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa and Central & South America. North America is likely to lead in the geographic category with the highest sales share and it is followed by Europe. The growing incidence of xerostomia and several dry mouth-related conditions like Sjogren's syndrome, rheumatoid arthritis, and HIV, along with an uptick in dry mouth literacy campaigns are primary variables leading to supremacy. For example, the Sjogren Syndrome Foundation of the United States is in charge of promoting consciousness and assisting patients with xerostomia in the United States and Canada. Due to considerations such as increasing healthcare spending, a rise in awareness-raising campaigns, and the proliferation of diseases including diabetes, HIV, cancer, and Parkinson's disease which trigger dry mouth complications, the Asia-Pacific region is presumed to record a lucrative CAGR throughout the forecast period.

Xerostomia Therapeutics Market Share and Competitor Analysis

GlaxoSmithKline PLC, Church & Dwight Co., Inc., Colgate-Palmolive Company, Hikma Pharmaceuticals PLC, Pendopharm, Sun Pharmaceuticals Industries Ltd., Lupin Pharmaceuticals, Inc., Pfizer, Inc., Parnell Pharmaceuticals, Inc., Acacia Pharma, and OraCoat are the major players in the xerostomia therapeutics market.

Please note: This is not an exhaustive list of companies profiled in the report.